Cargando…
Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects
PURPOSE: We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients. MATERI...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Sexual Medicine and Andrology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443994/ https://www.ncbi.nlm.nih.gov/pubmed/33151043 http://dx.doi.org/10.5534/wjmh.200082 |
_version_ | 1784568404263305216 |
---|---|
author | Lu, Yi Patrick. Fan, Shujun Liang, Zhen Song, Yuxuan Liu, Kang Zhou, Kechong Wang, Xiao Kang, Jiaqi Yang, Yongjiao Liu, Xiaoqiang |
author_facet | Lu, Yi Patrick. Fan, Shujun Liang, Zhen Song, Yuxuan Liu, Kang Zhou, Kechong Wang, Xiao Kang, Jiaqi Yang, Yongjiao Liu, Xiaoqiang |
author_sort | Lu, Yi Patrick. |
collection | PubMed |
description | PURPOSE: We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients. MATERIALS AND METHODS: The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online. RESULTS: After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is use was significantly associated with slightly increased risk of developing MM (OR: 1.13, 95% CI: 1.05 to 1.21, I(2)=67.1%), basal cell carcinoma (OR: 1.16, 95% CI: 1.13 to 1.19, I(2)=49.6%), and squamous cell carcinoma (OR: 1.07, 95% CI: 1.01 to 1.13, I(2)=0.0%). Totally, PDE5Is increased the risk of developing skin cancers (OR: 1.13, 95% CI: 1.09 to 1.17, I(2)=70.8%). TSA results showed that the sample size was enough to reach a positive conclusion. CONCLUSIONS: The use of PDE5Is may be slightly associated with increased risk of developing skin cancers. There should be a balance between drug benefits and potential safety issues. However, the pooled results should be considered tentative until confounding factors such as sun exposure and lifestyle are well-controlled in further studies. |
format | Online Article Text |
id | pubmed-8443994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Society for Sexual Medicine and Andrology |
record_format | MEDLINE/PubMed |
spelling | pubmed-84439942021-10-01 Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects Lu, Yi Patrick. Fan, Shujun Liang, Zhen Song, Yuxuan Liu, Kang Zhou, Kechong Wang, Xiao Kang, Jiaqi Yang, Yongjiao Liu, Xiaoqiang World J Mens Health Original Article PURPOSE: We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients. MATERIALS AND METHODS: The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online. RESULTS: After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is use was significantly associated with slightly increased risk of developing MM (OR: 1.13, 95% CI: 1.05 to 1.21, I(2)=67.1%), basal cell carcinoma (OR: 1.16, 95% CI: 1.13 to 1.19, I(2)=49.6%), and squamous cell carcinoma (OR: 1.07, 95% CI: 1.01 to 1.13, I(2)=0.0%). Totally, PDE5Is increased the risk of developing skin cancers (OR: 1.13, 95% CI: 1.09 to 1.17, I(2)=70.8%). TSA results showed that the sample size was enough to reach a positive conclusion. CONCLUSIONS: The use of PDE5Is may be slightly associated with increased risk of developing skin cancers. There should be a balance between drug benefits and potential safety issues. However, the pooled results should be considered tentative until confounding factors such as sun exposure and lifestyle are well-controlled in further studies. Korean Society for Sexual Medicine and Andrology 2021-10 2020-08-28 /pmc/articles/PMC8443994/ /pubmed/33151043 http://dx.doi.org/10.5534/wjmh.200082 Text en Copyright © 2021 Korean Society for Sexual Medicine and Andrology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lu, Yi Patrick. Fan, Shujun Liang, Zhen Song, Yuxuan Liu, Kang Zhou, Kechong Wang, Xiao Kang, Jiaqi Yang, Yongjiao Liu, Xiaoqiang Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title | Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title_full | Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title_fullStr | Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title_full_unstemmed | Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title_short | Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects |
title_sort | phosphodiesterase type 5 inhibitors and risk of skin cancers in men: a meta-analysis and trial sequential analysis involving 7,479,852 subjects |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443994/ https://www.ncbi.nlm.nih.gov/pubmed/33151043 http://dx.doi.org/10.5534/wjmh.200082 |
work_keys_str_mv | AT luyipatrick phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT fanshujun phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT liangzhen phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT songyuxuan phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT liukang phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT zhoukechong phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT wangxiao phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT kangjiaqi phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT yangyongjiao phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects AT liuxiaoqiang phosphodiesterasetype5inhibitorsandriskofskincancersinmenametaanalysisandtrialsequentialanalysisinvolving7479852subjects |